ORIC Pharmaceuticals plans Phase 3 enozertinib trial in lung cancer for first half of 2027

By Public Technologies
  • ORIC Pharmaceuticals plans to start Redwood-1, a global Phase 3 trial of enozertinib in first-line EGFR atypical lung cancer, in first-half 2027.
  • Phase 1b results presented at ESMO Congress 2026 showed tumor shrinkage, including brain metastases, with some brain tumors disappearing completely.
  • Treatment-related side effects caused no discontinuations; survival and response-duration findings remain immature.
  • The planned trial will enroll approximately 360 patients, comparing enozertinib with physician-selected osimertinib or afatinib.
  • Response results could support accelerated approval, while progression-free survival will underpin the full-approval assessment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230315PRIMZONEFULLFEED9851709) on October 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.